Acquiring Company
ARCHIMED
Acquired Company
ExcellGene
MontheyFinancial ServicesHealth CareVenture CapitalMedicalventure capital & private equityBiotechnologyDescription
Archimed has acquired a majority stake in Swiss-based ExcellGene and its sister company Magellan Biologics. This partnership aims to enhance the group's capabilities in gene transfer and cell culture-based manufacturing for biologics. Maria Wurm will continue as the group CEO, focusing on accelerating growth in the biosimilars market. Archimed's involvement is expected to support the development of complex recombinant proteins.
Quick answer
ARCHIMED is acquiring ExcellGene, announced September 29, 2025.
- How much did ARCHIMED pay for ExcellGene?
- The deal value was not disclosed.
- What does ARCHIMED do?
- ARCHIMED is a private equity firm focusing on the healthcare sector.
- Where are ARCHIMED and ExcellGene based?
- ExcellGene is based in Monthey, Valais, Switzerland.
- Who are the decision-makers at ARCHIMED?
- Fundz holds 1 contact at ARCHIMED. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Financial Services and Venture Capital
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Gryphon Digital Technologies merges with American Bitcoin (August 29, 2025)
- ARCHIMED acquires ZimVie, takes company private (November 6, 2025)
- ARCHIMED completes acquisition of ZimVie Inc. (October 20, 2025)
- Galecto, Inc. Acquires Damora Therapeutics, Inc. (November 10, 2025)
- Avanos Medical acquires Nexus Medical for growth (September 15, 2025)
- Edwards Lifesciences acquires Vectorious for $497M, $497M (September 4, 2025)
Who to call at ARCHIMED, and when
When ARCHIMED changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day ARCHIMED raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ARCHIMED, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ARCHIMED. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ARCHIMED makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired ExcellGene?
ExcellGene was acquired by ARCHIMED. The deal was reported on September 29, 2025. ARCHIMED is a private equity firm focusing on the healthcare sector. It invests in and supports companies that provide innovative solutions in medical technology and services. ARCHIMED is privately held and operates in Financial Services.
When did ARCHIMED acquire ExcellGene?
ARCHIMED's acquisition of ExcellGene was reported on September 29, 2025. Archimed has acquired a majority stake in Swiss-based ExcellGene and its sister company Magellan Biologics. This partnership aims to enhance the group's capabilities in gene transfer and cell culture-based manufacturing for biologics. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does ExcellGene do?
ExcellGene is a Swiss-based company specializing in biologic therapeutics, particularly in gene transfer and cell line development. It is privately held, operating in Biotechnology, and is based in Monthey.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.